The effect of β2glycoprotein I (β2GPI) and human monoclonal anticardiolipin antibody (aCL) on the protein S/C4b-binding protein (C4BP) system was evaluated. The binding of C4BP to protein S was assessed by ELISA in the presence of β2GPI with/without human monoclonal aCL. β2GPI downregulated the binding between S and C4BP significantly. Human monoclonal aCL abolished the β2GPI inhibitory effect in a calcium (Ca++) independent fashion. In separate experiments, the reactivity of aCL towards protein S in the presence or absence of β2GPI and cardiolipin was investigated. Monoclonal aCL bound to protein S only in the presence of a combination of β2GPI and cardiolipin. This binding was Ca++ dependent. These findings suggest that human monoclonal aCL increases the affinity of C4BP for protein S, and that protein S may represent one of the targets for aCL when combined with β2GPI and cardiolipin. Both issues may explain acquired free protein S deficiency and the attendant risk of thrombosis in patients with aCL.
Koike T. et al. Antiphospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus. Clin Exp Immunol1984; 56: 193-199.
Harris EN et al. Anti-cardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet1983; ii: 1211-1214.
4.
Harris EN et al. Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody testArch Intern Med1986; 146: 2153-2156.
5.
Roubey Ras.Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" antibodies. Blood1994; 84: 2854-2867.
6.
Galli M. et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet1990 ; 335: 952-953.
7.
Matsuura E. et al. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet1990; 336: 177-178.
8.
McNeil HP, Simpson RJ, Chesterman CN, Krilis SAAnti-phospholipid antibodies are directed against a complex antigen that induces a lipid-binding inhibitor of coagulation: β2glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA1990; 87: 4120-4124.
9.
Kato H., Enjyoji K.Amino acid sequence and location of the disulfide bonds in bovine β2glycoprotein I: The presence of five Sushi domains. Biochemistry1991; 30: 11687-11694.
10.
Ichinose A. , Bottenus RE, Davie EWStructure of transglutaminase. J Biol Chem1990; 265: 13411-13414.
11.
Matsuura E. et al. Molecular definition of human β2glycoprotein I (β2GPI) by cDNA cloning and inter species differences of β-2GPI in alternation anticardiolipin binding. Int Immunol1991; 3: 1217-1221.
12.
Matsuura E. et al. Anticardiolipin antibodies recognize β2glycoprotein I structure altered by interacting with an oxygen modified solid phase surface . J Exp Med1994; 179: 457-462.
13.
Nimpf J., Wurm H., Kostner M.Interaction of β2glycoprotein I with human blood platelets: Influences upon the ADP induced aggregation. Thromb Haemostas1985; 54: 397-401.
14.
Schousboe I. , Rasmussen MSSynchronized inhibition of the phospholipid mediated autoactivation of Factor XII in plasma by β2glycoprotein I and anti-β2-glycoprotein IThromb Haemostas1995; 73: 798-804.
15.
Schousboe I.β2glycoprotein I: Plasma inhibitor of contact activation of the intrinsic blood coagulation pathway. Blood1985; 66: 1086-1091.
16.
Shi W., Chong B., Hogg P., Chesterman C.Anticardiolipin antibodies block the inhibition by β2-glycoprotein I of the factor Xa generating activity of platelets. Thromb Haemostas1993; 70: 342-345.
17.
Bansci LF, van der Linden IK, Dertina RMβ2-glycoprotein I deficiency and the risk of thrombosis. Thromb Haemostas1992; 67: 649-653.
18.
Benedetti ED , Reber G., Miescher PANo increase of β2-glycoprotein I levels in patients with antiphospholipid antibodies. Thromb Haemost1992; 68: 624.
19.
Brighton TA et al. Beta2-glycoprotein I in thrombosis: evidence for a role as a natural anticoagulant. Br J Haematol1996; 93: 185-194.
20.
Esmon CTThe roles of protein C and thrombomodulin in the regulation of blood coagulation . J Biol Chem1989; 264: 4743-4746.
21.
Keeling DM et al. Role of β2-glycoprotein I and anti-phospholipid antibodies in activation of protein C in vitro. J Clin Pathol1993; 46: 908-911.
22.
Bokarewa MI , Blomback M., Egberg N., Rosen S.A new variant of interaction between phospholipid antibodies and the protein C system. Blood Coag Fibrinol1994; 5: 37-41.
23.
Dahlbäck B.Protein S and C4b-binding protein: Components involved in the regulation of the protein C anticoagulant system. Thromb Haemost1991; 66: 49-61.
24.
Schmidel DK et al. Organization of the human protein S gene . Biochemistry1990; 29: 7845-7852.
25.
Comp PC, Doray D., Patton D., Esmon CTAn abnormal plasma distribution of protein S occurs in functional protein S deficiency. Blood1986; 67: 504-508.
26.
Mann KG et al. Surface-dependent reactions of the vitamin K-dependent enzyme complex. Blood1990; 76: 1-16.
27.
Parke A. et al. The thrombotic diathesis associated with the presence of phospholipid antibodies may be due to low level of free protein SAm J Med1992; 93: 49-56.
28.
Forastiero R., Kordich L., Basilotta E., Carreras L.Differences in protein S and C4b-binding protein levels in different groups of patients with antiphospholipid antibodies. Blood Coag Fibrinol1994; 37: 1453-1461.
29.
Ichikawa K. et al. Reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome to β-2glycoprotein I. Arthritis Rheum1994; 37: 1453-1461.
30.
Matsuura E. et al. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol1992; 148: 3885-3891.
31.
Saeki T. et al. Evidence that C4b-binding protein is an acute phase protein . Biophys Res Commun1989; 164: 1446-1451.
32.
Frutos P., Alim R., Härdig, Dahlbäck B.Differential regulation of α and β chains of C4b-binding protein during acute-phase response resulting in stable plasma levels of free anticoagulant protein SBlood1994; 84: 815-822.
33.
Barnum SR, Dahlbäck B.C4b-binding protein, a regulatory component of the classical pathway of complement, is an acute phase protein and is elevated in systemic lupus erythematosus . Complement Inflamm1990; 7: 71-77.
34.
Keeling DM et al. Total and free protein S in systemic lupus erythematosus. Thrombosis Research1990; 60: 237-240.
35.
Ruiz-Argüelles GJ et al. Natural anticoagulant in systemic lupus erythematosus. Deficiency of protein S bound to C4bp associated with recent history thrombosis, antiphospholipid antibodies, and the antiphospholipid syndrome. J Rheumatol1991; 18: 552-558.
36.
Hillarp A., Dahlbäck B.Cloning of cDNA coding for the β-chain of human complement C4b-binding protein gene: sequence homology with the α-chain. Proc Natl Acad Sci USA1989; 87: 1183-1187.
37.
Griffin JH, Gruber A., Femandex JAReevaluation of total, free and bound protein S and C4b-binding protein levels in plasma anticoagulated with citrate or hirudin. Blood1992; 79: 3203-3211.
38.
Nelson RM, Long GLBinding of protein S to C4b-binding protein. J Biol Chem1992; 267: 8140-8145.
39.
Oosting JD et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanism?Blood1993; 81: 2618-2625.
40.
Wurm H.β2-glycoprotein (apolipoprotein H) interactions with phospholipid vesicles . Int J Biochem1984; 16: 511-515.
41.
Malia RG, Kitchen S., Greaves M., Preston FEInhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol1990; 76: 101-107.
42.
Ginsberg J. et al. Acquired free protein S deficiency is associated with antiphospholipid antibodies and increased thrombin generation in patients with systemic lupus erythematosus. Am J Med1995; 98: 379-383.
